NYSE: PFEPfizer Revenue
Pfizer revenue was $63.83B for the trailing 12 months ending Jun 29, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q2 2025) ending on Jun 29, 2025 was $14.7B, up 6.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, PFE annual revenue was $63.6B, with 6.8% growth year-over-year.
PFE past revenue growth
How has PFE's revenue growth performed historically?
Company
13.54%
Industry
14.87%
Market
17.61%
PFE's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PFE's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PFE's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
PFE revenue history
Current Revenue
$63.8B
Current Earnings
$10.8B
Current Profit Margin
16.8%
PFE's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when PFE announces revenue.
PFE Revenue History By Year
| PFE Yearly Revenue | PFE Revenue | PFE Change | PFE Revenue Growth |
|---|---|---|---|
| 2024‑12‑31 | $63.63B | $4.07B | +6.84% |
| 2023‑12‑31 | $59.55B | -$41.62B | -41.14% |
| 2022‑12‑31 | $101.18B | $19.89B | +24.46% |
| 2021‑12‑31 | $81.29B | $39.64B | +95.16% |
| 2020‑12‑31 | $41.65B | $746.00M | +1.82% |
| 2019‑12‑31 | $40.91B | $80.00M | +0.20% |
| 2018‑12‑31 | $40.83B | -$11.72B | -22.31% |
| 2017‑12‑31 | $52.55B | -$278.00M | -0.53% |
| 2016‑12‑31 | $52.82B | $3.97B | +8.13% |
| 2015‑12‑31 | $48.85B | -$754.00M | -1.52% |
| 2014‑12‑31 | $49.61B | -$1.98B | -3.84% |
| 2013‑12‑31 | $51.58B | -$3.07B | -5.62% |
| 2012‑12‑31 | $54.66B | -$6.38B | -10.45% |
| 2011‑12‑31 | $61.04B | -$4.13B | -6.34% |
| 2010‑12‑31 | $65.17B | $15.90B | +32.26% |
| 2009‑12‑31 | $49.27B | $973.00M | +2.01% |
| 2008‑12‑31 | $48.30B | -$122.00M | -0.25% |
| 2007‑12‑31 | $48.42B | $47.00M | +0.10% |
| 2006‑12‑31 | $48.37B | $966.00M | +2.04% |
| 2005‑12‑31 | $47.41B | -$1.58B | -3.23% |
| 2004‑12‑31 | $48.99B | $4.25B | +9.50% |
| 2003‑12‑31 | $44.74B | $12.44B | +38.53% |
| 2002‑12‑31 | $32.29B | $3.27B | +11.27% |
| 2001‑12‑31 | $29.02B | $2.98B | +11.44% |
| 2000‑12‑31 | $26.05B | -$1.12B | -4.13% |
| 1999‑12‑31 | $27.17B | $3.94B | +16.94% |
| 1998‑12‑31 | $23.23B | $12.18B | +110.14% |
| 1997‑12‑31 | $11.06B | $1.19B | +12.07% |
| 1996‑12‑31 | $9.86B | -$157.00M | -1.57% |
| 1995‑12‑31 | $10.02B | $2.04B | +25.62% |
| 1994‑12‑31 | $7.98B | $815.20M | +11.38% |
| 1993‑12‑31 | $7.16B | -$68.40M | -0.95% |
| 1992‑12‑31 | $7.23B | $280.20M | +4.03% |
| 1991‑12‑31 | $6.95B | N/A | N/A |
Pfizer Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.